scholarly journals Increases in c-Src Expression Level and Activity Do Not Promote the Growth of Human Colorectal Carcinoma Cells In Vitro and In Vivo

Neoplasia ◽  
2006 ◽  
Vol 8 (11) ◽  
pp. 905-IN2 ◽  
Author(s):  
Arkadiusz Welman ◽  
Christopher Cawthome ◽  
Lourdes Ponce-Perez ◽  
Jane Barraclough ◽  
Sarah Danson ◽  
...  
2006 ◽  
Vol 12 (20) ◽  
pp. 6194-6202 ◽  
Author(s):  
Manjinder Kaur ◽  
Rana P. Singh ◽  
Mallikarjuna Gu ◽  
Rajesh Agarwal ◽  
Chapla Agarwal

2019 ◽  
Vol 20 (8) ◽  
pp. 1917 ◽  
Author(s):  
Yixuan Xia ◽  
Chu Shing Lam ◽  
Wanfei Li ◽  
Md. Shahid Sarwar ◽  
Kanglun Liu ◽  
...  

Natural products, explicitly medicinal plants, are an important source of inspiration of antitumor drugs, because they contain astounding amounts of small molecules that possess diversifying chemical entities. For instance, Isodon (formerly Rabdosia), a genus of the Lamiaceae (formerly Labiatae) family, has been reported as a rich source of natural diterpenes. In the current study, we evaluated the in vitro anti-proliferative property of flexicaulin A (FA), an Isodon diterpenoid with an ent-kaurane structure, in human carcinoma cells, by means of cell viability assay, flow cytometric assessment, quantitative polymerase chain reaction array, Western blotting analysis, and staining experiments. Subsequently, we validated the in vivo antitumor efficacy of FA in a xenograft mouse model of colorectal carcinoma. From our experimental results, FA appears to be a potent antitumor molecule, since it significantly attenuated the proliferation of human colorectal carcinoma cells in vitro and restricted the growth of corresponsive xenograft tumors in vivo without causing any adverse effects. Regarding its molecular mechanism, FA considerably elevated the expression level of p21 and induced cell cycle arrest in the human colorectal carcinoma cells. While executing a non-apoptotic mechanism, we believe the antitumor potential of FA opens up new horizons for the therapy of colorectal malignancy.


Molecules ◽  
2012 ◽  
Vol 17 (4) ◽  
pp. 3844-3857 ◽  
Author(s):  
Wen-Cheng Chen ◽  
Tsu-Hsiang Kuo ◽  
Yi-Shiuan Tzeng ◽  
Ying-Chieh Tsai

2015 ◽  
Vol 11 (6) ◽  
pp. 4204-4210 ◽  
Author(s):  
YAPING WANG ◽  
RUIZHE QIAN ◽  
NING SUN ◽  
CHAO LU ◽  
ZONGYOU CHEN ◽  
...  

1995 ◽  
Vol 71 (2) ◽  
pp. 271-277 ◽  
Author(s):  
JE de Vries ◽  
WNM Dinjens ◽  
GK De Bruyne ◽  
HW Verspaget ◽  
EPM van der Linden ◽  
...  

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Dexin Shen ◽  
Yayun Fang ◽  
Fenfang Zhou ◽  
Zhao Deng ◽  
Kaiyu Qian ◽  
...  

Abstract Background CDCA3 is an important component of the E3 ligase complex with SKP1 and CUL1, which could regulate the progress of cell mitosis. CDCA3 has been widely identified as a proto-oncogene in multiple human cancers, however, its role in promoting human bladder urothelial carcinoma has not been fully elucidated. Methods Bioinformatic methods were used to analyze the expression level of CDCA3 in human bladder urothelial carcinoma tissues and the relationship between its expression level and key clinical characteristics. In vitro studies were performed to validate the specific functions of CDCA3 in regulating cell proliferation, cell migration and cell cycle process. Alterations of related proteins was investigated by western blot assays. In vivo studies were constructed to validate whether silencing CDCA3 could inhibit the proliferation rate in mice model. Results Bioinformatic analysis revealed that CDCA3 was significantly up-regulated in bladder urothelial carcinoma samples and was related to key clinical characteristics, such as tumor grade and metastasis. Moreover, patients who had higher expression level of CDCA3 tend to show a shorter life span. In vitro studies revealed that silencing CDCA3 could impair the migration ability of tumor cells via down-regulating EMT-related proteins such as MMP9 and Vimentin and inhibit tumor cell growth via arresting cells in the G1 cell cycle phase through regulating cell cycle related proteins like p21. In vivo study confirmed that silencing CDCA3 could inhibit the proliferation of bladder urothelial carcinoma cells. Conclusions CDCA3 is an important oncogene that could strengthen the migration ability of bladder urothelial carcinoma cells and accelerate tumor cell growth via regulating cell cycle progress and is a potential biomarker of bladder urothelial carcinoma.


1997 ◽  
Vol 25 (2) ◽  
pp. 264S-264S ◽  
Author(s):  
ROBERT BREW ◽  
JOHN S. ERIKSON ◽  
DAVID C. WEST ◽  
BRIAN F. FLANAGAN ◽  
STEPHEN E. CHRISTMAS

2013 ◽  
Vol 6 (4) ◽  
pp. 927-932 ◽  
Author(s):  
HAIBO WANG ◽  
ZHUANG YU ◽  
SHIHAI LIU ◽  
XIANGPING LIU ◽  
AIHUA SUI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document